--- title: 'Regulatory Daily Summary: What Happened on October 28, 2026' headline: Arrowhead wins UK authorization for Redemplo, with NICE backing description: The White House also prevailed in a dispute over the scope of the COINS rule. url: https://thebench.bio/news/regulatory/2026-10-28 topic: regulatory date: '2026-10-28' covers: - '2026-10-28' date_published: '2026-10-28T12:02:54Z' date_modified: '2026-10-28T12:02:54Z' tags: - Industry - Regulatory sources: 2 publisher: TheBench.Bio --- # Regulatory Daily Summary: What Happened on October 28, 2026 **Arrowhead wins UK authorization for Redemplo, with NICE backing** The White House also prevailed in a dispute over the scope of the COINS rule. ## Today in brief Arrowhead Pharmaceuticals secured UK authorization for Redemplo to lower triglycerides in adults with familial chylomicronemia syndrome. NICE recommended NHS funding in England and Wales for eligible adults with genetically confirmed disease whose condition isn’t adequately controlled by diet and standard treatments. [1] The White House prevailed over Treasury and HHS in a dispute over the COINS rule, whose scope the National Security Council broadened. [2] ## Redemplo gains UK authorization and a recommendation for NHS funding The UK Medicines and Healthcare products Regulatory Agency authorized Arrowhead’s Redemplo, or plozasiran, as an addition to diet to lower triglycerides in adults with familial chylomicronemia syndrome, a rare metabolic condition associated with very high triglyceride levels. [1] The authorization applies across the UK. NICE’s recommendation guides NHS care in England and Wales, covering adults with genetically confirmed disease whose condition remains inadequately controlled by diet and standard triglyceride-lowering treatments. [1] NICE’s recommendation is subject to a commercial arrangement. Northern Ireland has a separate validation process, while Scotland requires an independent reimbursement appraisal. [1] The authorization drew on PALISADE, a Phase 3 placebo-controlled study of 75 adults. Its primary measure compared the median percentage change from baseline in fasting triglycerides against placebo at month 10. [1] Arrowhead’s Europe head, Graham Skarnvad, said the company is focused on making plozasiran available in more European countries over the coming months. [1] ## The day in numbers - **75 adults**: Participants in PALISADE, the Phase 3 study supporting Redemplo’s UK authorization. [1] ## Also published - [Why we have clinical trials](), Biocene - [PACE panels tackle challenges to access and barriers to coverage](), Bio.News ## Sources 1. [Arrowhead gains UK marketing authorisation for Redemplo](), Pharmaceutical Technology, 2026-10-28 2. [White House beat Treasury, HHS in battle over COINS rule](), BioCentury, 2026-10-28 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: